× Industry Reports Services Press Release Contact us About us

Europe Bioreactors Market Size By Product Type (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By End-user (R&D Organizations, Biopharmaceutical Manufacturers, Contract Manufacturing Organizations [CMOs]), Industry Analysis Report, Regional Outlook (Germany, UK, Spain, Italy, France, Netherlands, Denmark, Russia, Poland, Sweden, Norway), Application Potential, Competitive Market Share & Forecast, 2020 - 2026
Published Date: October 2020 | Publisher: Graphical Research Report ID: GR1233 | Delivery : PDF  Request Free Sample

Report Content

Chapter 1.     Methodology

1.1.   Market definitions

1.2.   Forecast assumptions

1.3.   Data sources 

1.3.1.  Secondary

1.3.1.1.  Paid sources

1.3.1.2.      Unpaid sources

1.3.2.  Primary

Chapter 2.     Market Summary

2.1.   Europe bioreactors industry summary, 2015 – 2026

2.1.1.  Country trends

2.1.2.  Product type trends

2.1.3.  Cell trends

2.1.4.  Molecule trends

2.1.5.  End-user trends

Chapter 3.     Market Analysis

3.1.   Industry segmentation

3.2.   Industry outlook, 2015 - 2026

3.3.   Major factor analysis

3.3.1.  Drivers

3.3.1.1.   Increasing government funding for vaccine development

3.3.1.2.      Technological advancements in bioreactor industry

3.3.1.3.      Increasing number of pharmaceutical and biotechnology companies

3.3.1.4.      Rising demand for personalized medicines

3.3.2.  Restraints & challenges

3.3.2.1.   Limited storage capacity of single-use bioreactor

3.4.   Analysis of COVID-19 impact on the industry

3.5.   Porter’s analysis

3.6.   Competitive review, 2019

3.7.   PEST analysis

Chapter 4.         Europe Bioreactors Market Share, By Product Type

4.1.   Market trends

4.2.   Single-use

4.2.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

4.3.   Reusable

4.3.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

Chapter 5.         Europe Bioreactors Market Size, By Cell

5.1.   Market trends

5.2.   Mammalian cells

5.2.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

5.3.   Bacterial cells

5.3.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

5.4.   Yeast cells

5.4.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

5.5.   Others

5.5.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

Chapter 6.         Europe Bioreactors Market Trends, By Molecule

6.1.   Market trends

6.2.   Monoclonal antibodies

6.2.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

6.3.   Vaccines

6.3.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

6.4.   Recombinant proteins

6.4.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

6.5.   Stem cells

6.5.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

6.6.   Gene therapy

6.6.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

6.7.   Others

6.7.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

Chapter 7.         Europe Bioreactors Market Forecast, By End-user

7.1.   Market trends

7.2.   R&D organizations

7.2.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

7.3.   Biopharmaceutical manufacturers

7.3.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

7.4.   Contract Manufacturing Organizations (CMOs)

7.4.1.  Market estimates and forecast, by country, 2015 – 2026 (USD Million)

Chapter 8.         Europe Bioreactors Market Value, By Country

8.1.   Market trends

8.2.   Germany

8.2.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.2.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.2.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.2.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.3.   UK

8.3.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.3.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.3.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.3.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.4.   Spain

8.4.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.4.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.4.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.4.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.5.   Italy

8.5.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.5.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.5.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.5.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.6.   France

8.6.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.6.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.6.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.6.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.7.   Netherlands

8.7.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.7.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.7.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.7.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.8.   Denmark

8.8.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.8.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.8.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.8.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.9.   Russia

8.9.1.   Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.9.2.  Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.9.3.  Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.9.4.  Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.10. Poland

8.10.1. Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.10.2.          Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.10.3.          Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.10.4.          Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.11. Sweden

8.11.1. Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.11.2.          Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.11.3.          Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.11.4. Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

8.12. Norway

8.12.1. Market estimates and forecast, by product type, 2015 – 2026 (USD Million)

8.12.2.          Market estimates and forecast, by cell, 2015 – 2026 (USD Million)

8.12.3.          Market estimates and forecast, by molecule, 2015 – 2026 (USD Million)

8.12.4.          Market estimates and forecast, by end-user, 2015 – 2026 (USD Million)

Chapter 9.     Company Profiles

9.1.   Applikon Biotechnology, Inc. (Getinge AB)

9.1.1.   Business overview

9.1.2.  Financial data

9.1.3.  Product landscape

9.1.4.  Strategic outlook

9.2.   Bbi Biotech

9.2.1.   Business overview

9.2.2.  Financial data

9.2.3.  Product landscape

9.2.4.  Strategic outlook

9.3.   Cellexus Ltd.

9.3.1.   Business overview

9.3.2.  Financial data

9.3.3.  Product landscape

9.3.4.  Strategic outlook

9.4.   CerCell ApS

9.4.1.   Business overview

9.4.2.  Financial data

9.4.3.  Product landscape

9.4.4.  Strategic outlook

9.5.   Eppendorf AG

9.5.1.   Business overview

9.5.2.  Financial data

9.5.3.  Product landscape

9.5.4.  Strategic outlook

9.6.   Cytiva

9.6.1.   Business overview

9.6.2.  Financial data

9.6.3.  Product landscape

9.6.4.  Strategic outlook

9.7.   GEA Group AKtiengesellschaft

9.7.1.   Business overview

9.7.2.  Financial data

9.7.3.  Product landscape

9.7.4.  Strategic outlook

9.8.   Merck Group

9.8.1.   Business overview

9.8.2.  Financial data

9.8.3.  Product landscape

9.8.4.  Strategic outlook

9.9.   Pierre Guerin Sas

9.9.1.   Business overview

9.9.2.  Financial data

9.9.3.  Product landscape

9.9.4.  Strategic outlook

9.10. Sartorius Group

9.10.1. Business overview

9.10.2.          Financial data

9.10.3.          Product landscape

9.10.4.          Strategic outlook

9.11. Solaris Biotechnology Srl

9.11.1. Business overview

9.11.2.          Financial data

9.11.3.          Product landscape

9.11.4.          Strategic outlook

9.12. Thermo Fisher Scientific

9.12.1. Business overview

9.12.2.          Financial data

9.12.3.          Product landscape

9.12.4.          Strategic outlook

9.13. Solida Biotech GmbH

9.13.1. Business overview

9.13.2.          Financial data

9.13.3.          Product landscape

9.13.4.          Strategic outlook
 


Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]